3-溴-2-氟苯腈 | 840481-82-5

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯腈系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-2-氟苯腈
• 中文别名: 3-溴-2-氟苯甲腈；2-氟-3-溴苯腈
• 英文名称: 3-bromo-2-fluorobenzonitrile
• 英文别名: 2-fluoro-3-bromobenzonitrile
• CAS: 840481-82-5
• 化学式: C₇H₃BrFN
• 分子量: 200.01
• InChiKey: AMKVZJOQZLIOSL-UHFFFAOYSA-N

物化性质

• 熔点：
  37-40°C
• 沸点：
  221.9±20.0 °C(Predicted)
• 密度：
  1.69±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2926909090
• 危险性防范说明：
  P264,P270,P301+P312,P330,P501
• 危险性描述：
  H302
• 储存条件：
  存放于室温且干燥的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Bromo-2-fluorobenzonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-2-fluorobenzonitrile
CAS number: 840481-82-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H3BrFN
Molecular weight: 200

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-溴-2-氟苯腈是一种有机中间体，可通过两步反应从3-溴-2-氟苯甲酸制备得到。该化合物主要用作医药中间体，可用于合成STK4抑制剂。

反应信息

• 作为反应物：
  描述：

  3-溴-2-氟苯腈 在 sodium sulfide 、 盐酸 、 锌 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 1.0h， 以88%的产率得到3-bromo-2-mercaptobenzonitrile
  参考文献：
  名称：

  About the reaction of aryl fluorides with sodium sulfide: investigation into the selectivity of substitution of fluorobenzonitriles to yield mercaptobenzonitriles via SNAr displacement of fluorine

  摘要：

  In this report we describe a simple synthesis of mercaptobenzonitriles from the reaction of fluorobenzonitriles with Na2S in DMF at room temperature and following direct treatment with Zn/HCl. Significantly, 2- and 4-fluorobenzonitriles substituted with chlorine or bromine, from the reaction of but not iodine, undergo selective substitution of fluorine at room temperature to yield synthetically useful halo-substituted mercaptobenzonitriles. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.03.032
• 作为产物：
  描述：

  3-溴-2-氟苯甲酰胺 在 吡啶 、 三氟乙酸 作用下， 以 1,4-二氧六环 为溶剂， 以42%的产率得到3-溴-2-氟苯腈
  参考文献：
  名称：

  [EN] STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES
  [FR] INHIBITEURS STK4 POUR LE TRAITEMENT DE MALIGNITÉS HÉMATOLOGIQUES

  摘要：

  该申请涉及公式（I'）的化合物，该化合物调节激酶（例如STK4）的活性，包括该化合物的药物组合物，以及治疗或预防与激酶调节相关的疾病或紊乱的方法，如STK4。

  公开号：

  WO2016161145A1

文献信息

• DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20160002251A1

  公开（公告）日：2016-01-07

  The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

  本发明提供了一种二氢吡啶嗪-3,5-二酮衍生物或其盐，或化合物或盐的溶剂化合物，一种药物，一种药物组合物，一种钠依赖性磷酸盐转运体抑制剂，以及作为活性成分的化合物的高磷血症、继发性甲状旁腺功能亢进症、慢性肾功能衰竭、慢性肾病和与血管钙化相关的动脉硬化的预防和/或治疗剂，以及预防和/或治疗的方法。
• Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2)
  作者：Jayakanth Kankanala、Christophe Marchand、Monica Abdelmalak、Hideki Aihara、Yves Pommier、Zhengqiang Wang

  DOI：10.1021/acs.jmedchem.5b01973

  日期：2016.3.24

  isoquinoline-1,3-dione as a viable chemotype for selectively inhibiting TDP2. The initial hit compound 43 was identified by screening our in-house collection of synthetic compounds. Further structure–activity relationship (SAR) studies identified numerous analogues inhibiting TDP2 in low micromolar range without appreciable inhibition against the homologous TDP1 at the highest testing concentration

  酪氨酰DNA磷酸二酯酶II（TDP2）是最近发现的一种酶，可特异性修复拓扑异构酶II（Top2）毒物引起的DNA损伤并引起对这些药物的耐药性。预期抑制TDP2可增强临床上重要的靶向Top2的抗癌药的功效。但是，作为治疗靶标的TDP2仍然知之甚少。我们在此报告了异喹啉-1,3-二酮作为选择性抑制TDP2的可行化学型的发现。最初的打击化合物43通过筛选我们内部的合成化合物来鉴定。进一步的结构活性关系（SAR）研究发现，在最高测试浓度（111μM）下，许多类似物在低微摩尔范围内抑制TDP2，而对同源TDP1没有明显的抑制作用。最佳化合物64抑制重组TDP2，IC 50为1.9μM 。这种化学型的发现可以为理解TDP2作为药物靶标提供一个平台。
• [EN] SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE BICYCLIQUES SUBSTITUÉS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013049263A1

  公开（公告）日：2013-04-04

  Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

  披露了公式(I)的氮杂吲唑化合物：或其药用可接受盐，其中：X是O且Y是N；或者X是S且Y是CH；Z是CR2或N；Q是杂芳基；R1如本文所定义。还披露了使用这些化合物治疗至少一种与CYP17相关的病症的方法，例如，癌症，以及包含这些化合物的药物组合物。
• 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
  申请人：Saito Daisuke Roland

  公开号：US20090062333A1

  公开（公告）日：2009-03-05

  The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R 2 , R 7 , and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

  本发明提供了式(I)的8-氮杂双环[3.2.1]辛基-2-羟基苯甲酰胺化合物： 式中，R2、R7和m如说明书中所定义，或其药用可接受的盐，这些化合物是μ阿片受体的拮抗剂。本发明还提供了包含这些化合物的药物组合物，使用这些化合物治疗与μ阿片受体活性相关病症的方法，以及用于制备这些化合物的过程和中间体。
• Iron-Catalyzed C(sp2)–C(sp3) Cross-Coupling Reactions of Di(hetero)arylmanganese Reagents and Primary and Secondary Alkyl Halides
  作者：Paul Knochel、Maximilian Hofmayer、Jeffrey Hammann、Gérard Cahiez

  DOI：10.1055/s-0036-1590891

  日期：2018.1

  An iron-catalyzed cross-coupling between di(hetero)arylmanganese reagents and primary and secondary alkyl halides is reported. No rearrangement of secondary alkyl halides to unbranched products was observed in these C–C bond-forming reactions.

  报道了二（杂）芳基锰试剂与伯和仲烷基卤化物之间的铁催化交叉偶联。在这些 C-C 键形成反应中没有观察到仲烷基卤化物重排为未支化的产物。